Restrictive Pricing, Fewer Approvals Among Brexit Consequences, Report Says

Prospects look somewhat grim for the life sciences industry in the UK, regardless of whether the country decides to completely divorce itself from the EU or do a “soft exit,” a think tank says.

Facing budget constraints from a weaker post-Brexit economy, agencies involved in product reimbursement could make reimbursement more difficult in the country, the report said, with the National Institute of Health and Care Excellence possibly imposing stricter standards for proving cost-effectiveness.

It’s still too early to know whether the country will reach an agreement to retain certain EU policies in what would be considered a softer exit, but the report said the prime minister has indicated that the country could be leaning toward a complete breakoff.